Hey there, bargain hunter.
While the market’s been busy obsessing over semiconductors and rate cuts, biotech quietly went on one of the best runs in years. The SPDR S&P Biotech ETF has gained 61% over the past 12 months. The S&P 500 climbed 25% over the same stretch. Biotech won that race by a country mile, and most people missed it.
The two names showing up at the top of every search list right now: CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX). Very different risk profiles. Very different businesses. Both worth understanding.
What’s Driving the Sector
A few things are converging. New drug approvals staged a strong rebound coming out of 2025, and the momentum is carrying into this year. M&A activity has picked back up after a slow stretch — Gilead recently moved to acquire Arcellx for $7.8 billion, which sent a signal that large pharma is hungry again. And AI-assisted drug discovery is compressing timelines in ways that are starting to show up in pipeline velocity.
On top of that, pharma and biotech have defensive characteristics that are suddenly attractive to investors navigating uncertainty. When the market gets nervous, you want things people need regardless of what happens to GDP.
CRISPR Therapeutics: Early, Volatile, and Potentially Enormous
CRSP is a gene editing specialist. It co-developed Casgevy with Vertex, approved for sickle cell disease and transfusion-dependent beta-thalassemia. Casgevy has not generated much revenue yet — the administration process is complex, involving cell collection and editing outside the body, and the treatment is expensive. But CRISPR and Vertex have been making progress getting third-party payers on board.
The regulatory expansion move matters. The two partners recently filed to extend Casgevy’s approval to children between ages five and eleven. Approval there meaningfully expands the addressable market.
Beyond Casgevy, CRSP has a pipeline that includes CTX611, an anticoagulant designed to be administered just twice a year — which, if that works, is a major quality-of-life upgrade over daily dosing. One Wall Street analyst has suggested the stock could more than double from current levels based on pipeline value alone. The company had $2.4 billion in cash as of March 31 — not bad for a company worth around $5 billion. That cash runway gives it room to get products over the finish line without the dilution risk that kills smaller biotechs.
CRSP shares have climbed roughly 56% over the past year. Still, the stock is volatile. It dropped more than 6% in a single session recently on no specific news. Gene editing stocks do that. The catalysts — regulatory decisions, trial data, commercial milestones — move the stock dramatically in both directions.
Vertex Pharmaceuticals: The Monopoly With an Expanding Empire
Vertex is a different animal. It holds an effective monopoly in cystic fibrosis treatment, the only company marketing drugs that target the underlying cause of CF rather than just symptoms. That franchise got stronger with the December 2024 approval of Alyftrek, its next-generation CF drug.
What’s gotten interesting is what Vertex is doing beyond CF. Three things worth tracking:
- Casgevy: Vertex co-owns the gene editing therapy with CRISPR, collecting royalties as commercial uptake builds.
- Journavx: A non-opioid acute pain therapy that recently secured FDA approval. An entirely new revenue stream in a market that’s been desperate for alternatives to opioids for years.
- Povetacicept: A treatment for IgA nephropathy that posted positive Phase 3 results in March. A U.S. regulatory filing is already submitted, with potential approval possible by year-end.
Vertex’s stock has lagged the broader biotech rally, weighed down by some clinical setbacks and mixed results earlier in the year. That’s the part people skip. The CF franchise is still generating consistent earnings, and the pipeline is adding legs the market hasn’t fully priced in yet.
The Risk Side of This
Gene editing is still early. Clinical trial failures happen. Regulatory timelines slip. Casgevy’s commercial ramp has been slower than early projections suggested — partly because the logistics of administering it are genuinely complicated. A negative trial readout or a safety signal could move CRSP down 20-30% in a day. That’s the deal with high-conviction biotech.
For Vertex, the CF monopoly is the engine — but it also means if a competitor ever cracks that market, the stock faces a structural reset. Nothing on the immediate horizon suggests that’s imminent, but it’s worth knowing the risk exists.
Bull / Base / Bear
- Bull (CRSP): Casgevy wins pediatric approval, CTX611 data impresses, pipeline milestones stack up, stock revisits $80-$100.
- Base (CRSP): Casgevy ramps slowly, pipeline progresses without a knockout catalyst, stock holds the $55-$70 range.
- Bear (CRSP): Pipeline setback or payer coverage issues stall Casgevy, cash burn accelerates, stock retests lows.
- Bull (VRTX): Povetacicept gets year-end approval, Journavx ramps, CF holds, stock breaks above prior highs.
- Base (VRTX): CF generates steady earnings, pipeline inches forward, stock grinds higher in line with sector.
- Bear (VRTX): Povetacicept stumbles in regulatory review, Journavx uptake disappoints, stock gives back the year’s gains.
The Cheap Investor Scorecard
- XBI 12-month return: +61% vs. S&P 500 +25% — sector momentum is real
- CRSP cash position: $2.4 billion as of March 31 — strong runway
- CRSP market cap: ~$5 billion — cash covers nearly half of market cap
- VRTX CF franchise: Still the only approved mechanism-targeting drugs in the category
- Journavx (VRTX): FDA approved, non-opioid pain — watch Q2-Q3 adoption data
- Povetacicept: Phase 3 positive, U.S. filing submitted — potential year-end approval
- M&A environment: Active — Gilead/Arcellx deal at $7.8B signals appetite
- CRSP volatility: High — not for the faint-hearted
- Next major catalyst (CRSP): Pediatric Casgevy regulatory decision
- Next major catalyst (VRTX): Povetacicept approval timeline, Q2 Journavx sales
The second half of 2026 brings critical inflection points for both names. The XBI has already made its move. Whether CRSP and VRTX lead the next leg — or give some of it back — depends almost entirely on what comes out of the pipeline over the next six months. Worth watching closely.
